You are here: Industry Insights > TZLS-501

News List

USPTO grants patent to Tiziana for fully human monoclonal antibody, TZLS-501 expresspharma
August 25, 2020
The grant of this additional patent on TZLS-501 is of significance for the potential treatment of COVID-19 and other pulmonary diseases.
Tiziana Life Sciences signs manufacturing deal with STC Biologics pharmaceutical-technology
July 01, 2020
UK-based biotechnology firm Tiziana Life Sciences has executed an agreement with STC Biologics for the manufacture of TZLS-501 for clinical studies in Covid-19 patients.
Tiziana Developing TZLS-501 as Potential Coronavirus Treatment americanpharmaceuticalreview
March 13, 2020
Tiziana Life Sciences has announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.
Tiziana Life Sciences to expedite development of TZLS-501 for COVID-19 expresspharma
March 12, 2020
TZLS-501 is a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19.